Learn Treatment

Efficacy and Safety of Direct-Acting Antiviral Therapies and Baseline Predictors for Treatment Outcomes in Hepatitis C Patients in China

The data on direct-acting antivirals (DAAs) in chronic hepatitis C (CHC) patients in southern China with multiple genotypes circulating are limited.

A multicenter, real-world study, published in the Journal of Medical Virology, evaluated the efficacy and safety of DAA regimens among CHC patients in Guangdong, China.

The study abstract can be accessed here.